Immunohistochemical staining for P glycoprotein (Pgp)
Control* | MDR1 +8 T>C† | MDR1 IVS1−81 del G‡ | MSI-H§ | |||||
---|---|---|---|---|---|---|---|---|
Pgp expression | Normal mucosa (n=14) | Tumour (n=14) | Normal mucosa (n=11) | Tumour (n=11) | Normal mucosa (n=17) | Tumour (n=17) | Normal mucosa (n=12) | Tumour (n=12) |
*Colorectal cancer (CRC) patients with microsatellite stable tumours and without germline functional MDR1 polymorphisms were used as a control group. | ||||||||
†CRC patients with germline MDR1 promoter polymorphism (+8T>C). | ||||||||
‡CRC patients with germline MDR1 functional polymorphism in intron 1 (IVS81 delG). | ||||||||
§CRC patients with tumours exhibiting high microsatellite instability (MSI-H). | ||||||||
¶No of well differentiated tumours, No of moderately differentiated tumours, No of poorly differentiated tumours. | ||||||||
Low | 3 (21%) | 1 (7%) (0,0,1)¶ | 3 (27%) | 2 (18%) (0,1,1)¶ | 7 (41%) | 2 (12%) (0,0,2)¶ | 4 (33%) | 6 (50%) (0,0,6)¶ |
Moderate | 4 (29%) | 6 (43%) (1,5,0) | 6 (55%) | 4 (36%) (1,3,0) | 7 (41%) | 8 (47%) (2,6,0) | 4 (33%) | 1 (9%) (0,1,0) |
High | 7 (50%) | 7 (50%) (3,4,0) | 2 (18%) | 5 (46%) (2,3,0) | 3 (18%) | 7 (41%) (3,4,0) | 4 (33%) | 5 (40%) (1,4,0) |
All 54 (13,31,10)¶ | 14 | 14 (4,9,1) | 11 | 11 (3,7,1) | 17 | 17 (5,10,2) | 12 | 12 (1,5,6) |